Prevalence and management of chronic kidney disease in primary care patients in the UK

International Journal of Clinical Practice

Volumn 68, Issue 9, 2014, Pages 1110-1121

  Jameson, K ^a   Jick, S ^b   Hagberg, K W ^b   Ambegaonkar, B ^c   Giles, A ^d   O'Donoghue, D ^e  

^a Merck Sharp & Dohme Limited   (United Kingdom)

^b BOSTON UNIVERSITY   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

^d OXFORD PHARMAGENESIS LTD   (United Kingdom)

^e SALFORD ROYAL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT;

ADULT; ARTICLE; CHANGE MANAGEMENT; CHRONIC KIDNEY DISEASE; COMORBIDITY; DIABETES MELLITUS; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; MIDDLE AGED; PRIMARY MEDICAL CARE; RETROSPECTIVE STUDY; UNITED KINGDOM; ADOLESCENT; AGED; GLOMERULUS FILTRATION RATE; GREAT BRITAIN; PREVALENCE; PRIMARY HEALTH CARE; PROGNOSIS; RENAL INSUFFICIENCY, CHRONIC; STATISTICS AND NUMERICAL DATA;

ADOLESCENT; ADULT; AGED; ANTIHYPERTENSIVE AGENTS; DISEASE PROGRESSION; FEMALE; GLOMERULAR FILTRATION RATE; GREAT BRITAIN; HUMANS; HYPERTENSION; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PREVALENCE; PRIMARY HEALTH CARE; PROGNOSIS; RENAL INSUFFICIENCY, CHRONIC; RETROSPECTIVE STUDIES;

EID: 84908115786     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/ijcp.12454     Document Type: Article

References (43)

1. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39: S1-266.
2. de Lusignan S, Chan T, Stevens P et al. Identifying patients with chronic kidney disease from general practice computer records. Fam Pract 2005; 22: 234-41.
3. John R, Webb M, Young A, Stevens PE. Unreferred chronic kidney disease: a longitudinal study. Am J Kidney Dis 2004; 43: 825-35.
4. Astor BC, Matsushita K, Gansevoort RT et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. Kidney Int 2011; 79: 1331-40.
5. de Lusignan S, Gallagher H, Chan T et al. The QICKD study protocol: a cluster randomised trial to compare quality improvement interventions to lower systolic BP in chronic kidney disease (CKD) in primary care. Implement Sci 2009; 4: 39.
6. Coresh J, Astor BC, Greene T et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003; 41: 1-12.
7. Crowe E, Halpin D, Stevens P. Early identification and management of chronic kidney disease: summary of NICE guidance. BMJ 2008; 337: a1530.
8. Rucker D, Tonelli M. Cardiovascular risk and management in chronic kidney disease. Nat Rev Nephrol 2009; 5: 287-96.
9. Levey AS, Coresh J, Balk E et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003; 139: 137-47.
10. Remuzzi G, Ruggenenti P, Perico N. Chronic renal diseases: renoprotective benefits of renin-angiotensin system inhibition. Ann Intern Med 2002; 136: 604-15.
11. Fellstrom BC, Jardine AG, Schmieder RE et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009; 360: 1395-407.
12. Wanner C, Krane V, Marz W et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353: 238-48.
13. Navaneethan SD, Perkovic V, Johnson DW et al. HMG CoA reductase inhibitors (statins) for kidney transplant recipients. Cochrane Database Syst Rev 2009; CD005019.
14. Navaneethan SD, Pansini F, Perkovic V et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev 2009; CD00784.
15. Baigent C, Landray MJ, Reith C et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011; 377: 2181-92.
16. McCullough PA. Why is chronic kidney disease the "spoiler" for cardiovascular outcomes? J Am Coll Cardiol 2003; 41: 725-8.
17. Patel UD, Ou FS, Ohman EM et al. Hospital performance and differences by kidney function in the use of recommended therapies after non-ST-elevation acute coronary syndromes. Am J Kidney Dis 2009; 53: 426-37.
18. Tonelli M, Pfeffer MA. Kidney disease and cardiovascular risk. Annu Rev Med 2007; 58: 123-39.
19. Moynihan R, Glassock R, Doust J. Chronic kidney disease controversy: how expanding definitions are unnecessarily labelling many people as diseased. BMJ 2013; 347: f4298.
20. Department of Health. The National Service Framework for Renal Services, Part Two: Chronic Kidney Disease, Acute Renal Failure and End of Life Care, 2005. https://www.gov.uk/government/uploads/sys tem/uploads/attachment-data/file/199002/National- Service-Framework-for-Renal-Services-Part-Two-Chronic-Kidney-Disease-acute-Renal-Failure- andendof-Life-Care.pdf (accessed 30 October 2013).
21. NHS. National Quality and Outcomes Framework Statistics for England 2006/07, 2007. https://cata logue.ic.nhs.uk/publications/primary-care/qof/qualoutc- fram-06-07/qof-eng-06-07-bull-rep.pdf (accessed 13 May 2013).
22. Stevens PE, O'Donoghue DJ, de Lusignan S et al. Chronic kidney disease management in the United Kingdom: NEOERICA project results. Kidney Int 2007; 72: 92-9.
23. de Lusignan S, Tomson C, Harris K et al. Creatinine fluctuation has a greater effect than the formula to estimate glomerular filtration rate on the prevalence of chronic kidney disease. Nephron Clin Pract 2011; 117: c213-24.
24. Craig R, Mindell J. Health Survey for England 2010 respiratory health: summary of key findings, 2010. https://catalogue.ic.nhs.uk/publications/public-heal th/surveys/heal-surv-resp-heal-eng-2010/heal-surveng- 2010-resp-heal-summ-rep.pdf (accessed 30 October 2013).
25. Eriksen BO, Ingebretsen OC. The progression of chronic kidney disease: a 10-year population-based study of the effects of gender and age. Kidney Int 2006; 69: 375-82.
26. Hemmelgarn BR, Zhang J, Manns BJ et al. Progression of kidney dysfunction in the community- dwelling elderly. Kidney Int 2006; 69: 2155-61.
27. Li L, Astor BC, Lewis J et al. Longitudinal progression trajectory of GFR among patients with CKD. Am J Kidney Dis 2012; 59: 504-12.
28. Karunaratne K, Stevens P, Irving J et al. The impact of pay for performance on the control of blood pressure in people with chronic kidney disease stage 3-5. Nephrol Dial Transplant 2013; 7: 7.
29. O'Donoghue DJ. Going upstream: the implication and opportunities of early detection. J Ren Care 2009; 35(Suppl. 2): 3-7.
30. Jick SS, Kaye JA, Vasilakis-Scaramozza C et al. Validity of the general practice research database. Pharmacotherapy 2003; 23: 686-9.
31. Jick S, Hagberg K, O'Donoghue D et al. Prevalence, associated comorbidities, and treatment patterns among chronic kidney disease patients: an analysis using UK GPRD data. Value Health 2012; 15: A362.
32. NHS Business Services Authority. ACE inhibitors and angiotensin-II receptor antagonists, July-September 2009. http://www.nhsbsa.nhs.uk/Documents/ July-Sept-09aCE-InhibitorsandaIIRAs.pdf (accessed 13 May 2013).
33. NHS Prescription Services. Cardiovascular system national charts. November 2011. http://www. nhsbsa.nhs.uk/PrescriptionServices/Documents/PPD PrescribingAnalysisCharts/Cardio-Nov-2011-Natio nal.pdf (accessed 13 May 2013).
34. Sikaneta T, Abdolell M, Taskapan H et al. Variability in CKD stage in outpatients followed in two large renal clinics. Int Urol Nephrol 2012; 44: 1461-6.
35. National Institute for Health and Clinical Excellence. NICE Clinical Guideline 67. Lipid Modification: Cardiovascular Risk Assessment and the Modification of Blood Lipids for the Primary and Secondary Prevention of Cardiovascular Disease. London: NICE, 2008.
36. British Cardiac Society BHS, Diabetes UK, HEART UK, Primary Care Cardiovascular Society, The Stroke Association. JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005; 91: v1-52.
37. Onuigbo MA. Can ACE inhibitors and angiotensin receptor blockers be detrimental in CKD patients? Nephron Clin Pract 2011; 118: 7.
38. Onuigbo MA, Onuigbo NT. Late-onset renal failure from angiotensin blockade (LORFFAB) in 100 CKD patients. Int Urol Nephrol 2008; 40: 233-9.
39. Ahmed AK, Kamath NS, El Kossi M, El Nahas AM. The impact of stopping inhibitors of the renin-angiotensin system in patients with advanced chronic kidney disease. Nephrol Dial Transplant 2010; 25: 3977-82.
40. National Institute of Health Research. EME - 11/ 30/07: Multi-centre Randomized Controlled Trial of angiotensin converting enzyme inhibitor (ACEi)/ angiotensin receptor blocker (ARB) - withdrawal in chronic kidney disease STOP-ACEi-STUDY (SAS). http://www.nets.nihr.ac.uk/projects/eme/ 113007 (accessed 27 January 2014).
41. National Institute for Health and Clinical Excellence. CG114 Anaemia Management in People with Chronic Kidney Disease. London: NICE, 2011.
42. Levey AS, Bosch JP, Lewis JB et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-70.
43. Lewis J, Agodoa L, Cheek D et al. Comparison of cross-sectional renal function measurements in African Americans with hypertensive nephrosclerosis and of primary formulas to estimate glomerular filtration rate. Am J Kidney Dis 2001; 38: 744-53.